KDDF Links With HUYA For Cross-Border R&D Opportunities
This article was originally published in PharmAsia News
The state-run Korea Drug Development Fund, which provides support to promising new R&D projects at South Korean companies, has begun to explore additional opportunities to bring in innovative drug compounds from overseas to prop up South Korean pharmas’ pipelines, amid the country's ongoing efforts to become a developer of novel global drugs.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.